ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Joint NCI/FDA Program approved; ‘May Solve Our Differences’

December 15, 1989

White House Preparing To Nominate Andrew von Eschenbach as FDA Commissioner, Sources Said

March 3, 2006

Psychiatric Disorders Often Overlooked By Oncologists

September 28, 2007

Proceedings Initiated Against Two Physicians At Dana-Farber

April 7, 1995

Clinical Trial Participants Sue Duke University, Potti, Nevins and Others for Causing Harm

September 9, 2011

Copeland Named Director, UF Cancer Center

February 10, 1995